Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 13th. The shares were sold at an average price of $219.56, for a total transaction of $3,293,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Stephen Hoge also recently made the following trade(s):

  • On Monday, December 27th, Stephen Hoge sold 5,000 shares of Moderna stock. The shares were sold at an average price of $243.10, for a total transaction of $1,215,500.00.
  • On Thursday, December 23rd, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $247.30, for a total transaction of $3,709,500.00.
  • On Monday, December 13th, Stephen Hoge sold 20,000 shares of Moderna stock. The stock was sold at an average price of $257.01, for a total value of $5,140,200.00.
  • On Thursday, December 2nd, Stephen Hoge sold 10,000 shares of Moderna stock. The stock was sold at an average price of $301.29, for a total value of $3,012,900.00.
  • On Monday, November 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $231.01, for a total value of $3,465,150.00.
  • On Friday, November 12th, Stephen Hoge sold 5,000 shares of Moderna stock. The stock was sold at an average price of $225.86, for a total value of $1,129,300.00.
  • On Wednesday, November 3rd, Stephen Hoge sold 10,000 shares of Moderna stock. The stock was sold at an average price of $350.00, for a total value of $3,500,000.00.
  • On Monday, October 25th, Stephen Hoge sold 20,000 shares of Moderna stock. The stock was sold at an average price of $331.80, for a total value of $6,636,000.00.

Shares of Moderna stock opened at $204.73 on Friday. Moderna, Inc. has a 1 year low of $117.34 and a 1 year high of $497.49. The firm has a market cap of $83.01 billion, a PE ratio of 12.55, a P/E/G ratio of 0.28 and a beta of 1.22. The stock has a fifty day moving average price of $259.66 and a 200-day moving average price of $320.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.35 and a quick ratio of 1.25.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 4th. The company reported $7.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.49 by ($1.79). Moderna had a net margin of 59.69% and a return on equity of 121.61%. The business had revenue of $4.97 billion for the quarter, compared to analysts’ expectations of $6.29 billion. During the same period in the prior year, the business earned ($0.59) earnings per share. The company’s revenue for the quarter was up 3065.0% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post 26.32 EPS for the current fiscal year.

A number of equities analysts recently issued reports on MRNA shares. Wolfe Research began coverage on Moderna in a report on Monday, November 8th. They issued an “outperform” rating and a $304.00 target price on the stock. Argus dropped their price objective on Moderna from $420.00 to $350.00 in a research note on Thursday, January 6th. Jefferies Financial Group dropped their price objective on Moderna from $375.00 to $325.00 and set a “hold” rating on the stock in a research note on Friday, November 5th. TheStreet upgraded Moderna from a “c+” rating to a “b-” rating in a research note on Monday, November 1st. Finally, Piper Sandler dropped their price objective on Moderna to $348.00 and set an “overweight” rating on the stock in a research note on Friday, November 5th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $251.81.

A number of institutional investors and hedge funds have recently made changes to their positions in MRNA. Corbenic Partners LLC bought a new position in Moderna in the 3rd quarter worth about $25,000. Gradient Investments LLC boosted its position in shares of Moderna by 2,000.0% during the 4th quarter. Gradient Investments LLC now owns 105 shares of the company’s stock valued at $27,000 after acquiring an additional 100 shares during the last quarter. Evermay Wealth Management LLC bought a new stake in shares of Moderna during the 2nd quarter valued at about $28,000. Hall Laurie J Trustee bought a new stake in shares of Moderna during the 4th quarter valued at about $28,000. Finally, Girard Partners LTD. bought a new stake in shares of Moderna during the 3rd quarter valued at about $29,000. 59.11% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: Black Swan

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.